Business Information
The group's principal activity is to discover, develop, manufacture and market gene-based drugs to treat and cure disease. The group has ten products in clinical development, including drugs to treat such diseases as cancer, rheumatoid arthritis, lupus, hepatitis c, chronic venous ulcers, growth hormone deficiency and immunodeficiencies. The group focuses its internal product development efforts on novel human protein and antibody drugs discovered through genomics-based research and on new improved long-acting versions of existing protein drugs created using proprietary albumin fusion technology. The group uses collaborations for the development of gene therapy products, small molecule drugs and diagnostic products discovered using its genomics-based technology.
|
|
Name |
Title
|
Email
|
| Argeris Karabelas | Chmn. | N/A | | Timothy Barabe | CFO, Sr. VP | N/A | | Barry Labinger | Exec. VP, Chief Commercial Officer | N/A | | Curran Simpson | Sr. VP - Operations | N/A | | Daniel Gold | Sr. VP - Manufacturing Alliances | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 25,755 | (251,173) | | 2005 | 19,113 | (239,439) | | 2004 | 3,831 | (242,898)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
